Live Online Policy Forum 

# Politics, Science, and Money: The Collective Meltdown over the New Alzheimer’s Drug 

##### Watch the Event 

Download:

[ 

Video 

](https://fastly-unsigned-us-east-1-prod.brightcovecdn.com/media/v1/pmp4/static/clear/6039378657001/009e194a-21e6-49c6-9f58-dc4809dd3e99/71e2b34d-fd5e-4179-852d-b98ddd3cb93d/main.mp4) 

[ 

Audio 

](https://assets.pippa.io/shows/5e2e15a046f4465f31c89d8c/1626804336423-ce17cf15a05d958b447649cf7782b7ee.mp3) 

Join the conversation on X using [\#CatoHealth](https://x.com/hashtag/CatoHealth). Follow [@CatoInstitute](https://x.com/catoinstitute) on X to get future event updates, live streams, and videos from the Cato Institute.

Date and Time 

July 20, 2021 12 - 1 PM EDT 

Location 

Live Online 

Share This Event 

##### Featuring 

![Nicholas Bagley headshot cropped](/sites/cato.org/files/styles/author_picture/public/2021-06/Bagley_Nick.png?itok=lndYHASQ) 

Nicholas Bagley 

Professor of Law, University of Michigan Law School

[ 

](https://twitter.com/nicholas_bagley) 

[![Media Name: dhyman.jpg](/sites/cato.org/files/styles/author_picture/public/authors/crops/dhyman.jpg?itok=LfUKw9cY)](/people/david-hyman) 

[David A. Hyman](/people/david-hyman)

Scott K. Ginsburg Professor of Health Law and Policy, Georgetown University Law Center; Adjunct Scholar, Cato Institute

[![Michael F. Cannon](/sites/cato.org/files/styles/author_picture/public/2021-01/Michael%20Cannon.jpg?itok=0UROn8Dc)](/people/michael-f-cannon) 

[Michael F. Cannon](/people/michael-f-cannon)

Director of Health Policy Studies, Cato Institute

[ 

](https://x.com/mfcannon) [ 

](mailto:mcannon@cato.org) 

[![jeff-singer-cropped.jpg](/sites/cato.org/files/styles/author_picture/public/2024-05/jeff-singer-cropped.jpg?itok=G_0nEnx7)](/people/jeffrey-singer) 

[Jeffrey A. Singer](/people/jeffrey-singer)

Senior Fellow, Cato Institute

[ 

](https://x.com/dr4liberty) [ 

](mailto:jsinger@cato.org) 

In June, the Food and Drug Administration gave marketing approval to the Alzheimer’s drug Aduhelm, against the unanimous advice of its advisory panel. Three of the panel’s five members resigned in protest. The panel’s members and many other medical experts claim there is no convincing evidence that the drug provides clinical benefit. Other critics complain that what they see as a useless drug will now cost Medicare (and taxpayers) $56,000 per patient per year.

The Aduhelm controversy brings into focus long-standing arguments against efficacy requirements for FDA drug approval, especially when the FDA also permits practitioners to prescribe any approved drugs “off label,” deferring to their expertise and clinical judgment. The controversy also directs attention to federal laws that require Medicare to cover most FDA-approved drugs and prohibit Medicare from negotiating drug prices.

Experts on health care, health and regulatory law, and health economics will explore these and related issues in what promises to be a lively discussion.

### Additional Resources

- [Controversy Over New Alzheimer’s Drug Challenges FDA Efficacy Requirement](https://www.cato.org/blog/controversy-over-new-alzheimers-drug-challenges-need-fda-efficacy-requirement)
- [The Drug That Could Break American Health Care](https://www.theatlantic.com/ideas/archive/2021/06/aduhelm-drug-alzheimers-cost-medicare/619169/)
- [Why Does Wall Street Love Trump’s Ineffective Drug-price Plan?](https://www.statnews.com/2018/05/14/trump-drug-price-plan-wall-street/)
- [Drug Reformation: End Government’s Power to Require Prescriptions](https://www.cato.org/white-paper/drug-reformation-end-governments-power-require-prescriptions)

[![Creative Commons License](/build/cato_2020/images/creative-commons.svg)](http://creativecommons.org/licenses/by-nc-sa/4.0/) 
This work is licensed under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).